Overactive Bladder Treatment Market size was over USD 5.17 billion in 2024 and is projected to cross USD 11.8 billion by the end of 2037, growing at more than 6.7% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of overactive bladder treatment is estimated at USD 5.44 billion.
The reason behind the growth is impelled by the growing number of pregnancies. Women go through hormonal changes during pregnancy, which may compromise bladder control and cause symptoms of overactive bladder. The hormone progesterone in particular may encourage bladder muscle relaxation, resulting in increased frequency and urgency of urinating.
The growing inclination toward minimally invasive procedures is believed to fuel the market growth. The need for a shorter hospital stay, less discomfort, and fewer complications has increased the preference for minimally invasive surgery among the general public worldwide. Nonpharmacological treatments such as oral medications have been found to lessen the signs and improve bladder function by strengthening the pelvic floor and altering behavior.
In addition, techniques including neuromodulation, sacral nerve stimulation, and percutaneous tibial nerve stimulation are among the minimally invasive procedures which have gained popularity since they can manage overactive bladder symptoms in patients without the requirement of any surgery. According to research, over 12 million laparoscopic procedures are performed across the globe every year.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
6.7% |
|
Base Year Market Size (2024) |
USD 5.17 billion |
|
Forecast Year Market Size (2037) |
USD 11.8 billion |
|
Regional Scope |
|
Therapy (Anticholinergics, Mirabegron, Neurostimulation, Intravesical Instillation)
The neurostimulation segment is estimated to hold around 40% share of the overactive bladder treatment market in the coming years owing to the benefits offered by neurostimulation therapy. Overactive bladder (OAB) may be treated with neurostimulation, which uses a neurostimulator device to stimulate the sacral nerves. This has the potential to control bladder function and lessen the symptoms of OAB including frequent and urgent urination.
Moreover, neurostimulation is typically performed as an outpatient procedure and is comparatively non-invasive to other procedures. Additionally, compared to medicines, which could result in constipation, dry mouth, and other side effects neurostimulation has fewer systemic side effects.
Disease Type (Idiopathic Overactive Bladder, Neurogenic Overactive Bladder)
The idiopathic overactive bladder segment in the overactive bladder treatment market is set to garner a notable share of over 50% in the near future. Overactive bladder caused by idiopathic causes is more common than overactive bladder caused by neurogenic causes and the majority of OAB and detrusor overactivity instances are "idiopathic”. The symptoms describe OAB symptoms for which there is no underlying cause such as found in obesity. Since OAB symptoms including urge incontinence, and urine urgency could be effectively decreased or eliminated with overactive bladder treatment, it is often used to treat idiopathic OAB.
Our in-depth analysis of the global market includes the following segments:
|
Therapy |
|
|
Disease Type |
|
North American Market Forecast
Overactive bladder treatment market in North America is predicted to account for the largest share of over 40% by the end of 2037 impelled by the growing investment in healthcare. As a result, there is a growing awareness among people in the region about overactive bladder as a medical condition which makes it simpler for people with overactive bladder to get the care they need and the tools they require to manage their illness. According to estimates, health spending in the US increased by over 9% in 2020.
APAC Market Statistics
The Asia Pacific overactive bladder treatment market is estimated to be the second largest, during the forecast timeframe led by the growing prevalence of chronic conditions such as diabetes. For instance, diabetes is linked to nerve degeneration, which may hinder bladder function and induce overactive bladder symptoms. As a result, the need for overactive bladder treatment may increase in the area. According to estimates, India has the highest prevalence of diabetes in the world as more than 70 million people currently living with the disease and the figure is projected to rise to over 130 million by 2045.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?